Last Update 12 Aug 26
Fair value Increased 5.67%CAH: Generic Conversion Strength Will Support Earnings Execution Into FY27
The analyst price target for Cardinal Health has moved from about $250.53 to about $264.73, with analysts pointing to recent target raises across the Street that reference strong execution, updated estimates into FY27, and support from generic conversion activity and brand-to-generic trends.
Analyst Commentary
Recent research on Cardinal Health centers on higher price targets, updated earnings forecasts into FY27, and the impact of brand to generic trends. Analysts are refining their views on the stock as they factor in recent results and management commentary on generic conversion activity and execution.
Bullish Takeaways
- Bullish analysts are lifting price targets into a range around US$250 to just under US$300, which signals greater confidence in Cardinal Health's earnings power versus prior models.
- Several research notes cite strong execution and fiscal Q2 and Q4 performance as key reasons to raise estimates, which supports the view that recent results are tracking ahead of earlier expectations.
- Updated models into FY27 assume that brand to generic conversion and generic launch activity remain supportive for margins, which these analysts see as important for Cardinal Health's growth profile.
- Some bullish analysts indicate that Cardinal Health could guide FY27 adjusted EPS above previous long range planning targets, which they see as helpful for justifying higher valuation multiples.
Bearish Takeaways
- Even within generally positive commentary, there is an emphasis on the need for Cardinal Health to "clear the bar" set by higher expectations into FY27, which highlights execution risk around these raised targets.
- Higher price targets and stronger estimates leave less room for disappointment if generic trends or conversion activity slow, which could pressure valuation if earnings fall short of the updated projections.
- The focus on robust brand to generic conversion in recent quarters underlines a reliance on this driver. If this trend normalizes, it could make it harder for Cardinal Health to sustain the same level of earnings growth assumed in current models.
What is in the News for Cardinal Health
- Major Pharmaceuticals, an affiliate distributed by Cardinal Health, is carrying out ongoing voluntary nationwide Class II recalls of certain subpotent levothyroxine tablet lots, which puts product quality controls and regulatory exposure under closer scrutiny. Source: recent recall disclosures and FDA event details.
- Cardinal Health announced that finance executive Anita Zielinski, with prior roles at Baxter and Sysco, will become Chief Accounting Officer in November 2026. This puts fresh focus on the company’s financial reporting and governance framework. Source: company leadership announcement.
- Major Pharmaceuticals initiated recalls of specific levothyroxine 125 mcg tablet lots in July 2026, classified as Class II, with voluntary firm-initiated action and nationwide US distribution. The status of this recall remains ongoing as of August 2026. Source: FDA recall Event ID 99399.
- Additional recalls of certain levothyroxine 25 mcg tablet lots were also initiated in July 2026 as Class II, with the same voluntary and nationwide pattern. This adds to Cardinal Health’s current product-related risk profile. Source: FDA recall Event ID 99399.
- From April 1, 2026 to June 30, 2026 Cardinal Health repurchased 1,960,591 shares for US$405.44m under its June 2023 buyback program and has completed 13,680,555 shares for US$2,083.96m in total, alongside a new Board-authorized share repurchase program of up to US$5,000m announced in early August 2026.
Valuation Changes for Cardinal Health
- Fair Value has risen modestly from $250.53 to $264.73, reflecting a slightly higher assessed worth per share.
- The Discount Rate has moved up slightly from 7.11% to 7.24%, implying a marginally higher required return in the updated model.
- Revenue Growth has been reduced from 7.82% to 6.01%, indicating a more conservative view on Cardinal Health's future dollar revenue expansion.
- Net Profit Margin has shifted from 0.73% to 0.80%, indicating a small uplift in expected profitability on each dollar of sales.
- Future P/E has edged lower from 29.56x to 28.84x, suggesting a slightly reduced multiple applied to Cardinal Health's projected earnings.
0 viewsusers have viewed this narrative update
Key Takeaways
- Growth in pharmaceuticals and specialty distribution is driven by demographic trends, with diversification into specialty and home healthcare strengthening future earnings potential.
- Efficiency gains from automation and portfolio optimization are expected to improve margins, cash flow, and profit resilience amid ongoing healthcare industry changes.
- Increasing regulatory pressures, competitive threats, customer dependence, and evolving reimbursement risks could compress margins and constrain Cardinal Health's long-term growth prospects.
Catalysts
About Cardinal Health- Operates as a healthcare services and products company in the United States, Canada, Europe, Asia, and internationally.
- Cardinal Health is well-positioned to benefit from increasing global demand for pharmaceuticals and medical supplies driven by an aging population and the rising prevalence of chronic diseases, which is leading to robust pharmaceutical volumes and consistent revenue growth in core and specialty distribution-positively impacting future top-line revenue.
- The company's investments in automation, advanced supply chain technology, and new distribution centers are expected to deliver long-term operational efficiencies and cost savings, supporting improved net margins and free cash flow as healthcare shifts to value-based and outpatient models.
- Strategic expansion into higher-margin specialty businesses, including acquisitions in multi-specialty MSO platforms (e.g., Solaris Health), specialty pharma, and biopharma solutions, should accelerate long-term profit growth, diversify revenue streams, and enhance overall earnings resilience.
- The strong performance and continued investment in Other growth businesses such as at-Home Solutions, Nuclear and Precision Health, and OptiFreight Logistics aligns with the growing trend of outpatient and home healthcare-underpinning diversified revenue growth and supporting margin expansion.
- Ongoing efforts to optimize the generic drug portfolio and scale Cardinal Health-branded medical products are yielding higher profitability versus branded counterparts and are expected to further enhance gross profit and operating margins, reinforcing long-term earnings growth.
Cardinal Health Future Earnings and Revenue Growth
Assumptions
How have these above catalysts been quantified?
- Analysts are assuming Cardinal Health's revenue will grow by 6.0% annually over the next 3 years.
- Analysts assume that profit margins will increase from 0.7% today to 0.8% in 3 years time.
- Analysts expect earnings to reach $2.4 billion (and earnings per share of $11.68) by about August 2029, up from $1.7 billion today. The analysts are largely in agreement about this estimate.
- In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 29.0x on those 2029 earnings, down from 31.8x today. This future PE is greater than the current PE for the US Healthcare industry at 24.7x.
- Analysts expect the number of shares outstanding to decline by 2.6% per year for the next 3 years.
- To value all of this in today's terms, we will use a discount rate of 7.24%, as per the Simply Wall St company report.
Risks
What could happen that would invalidate this narrative?- Increasing government regulation and pricing scrutiny, as referenced by the company managing through "regulatory uncertainty" and "the implementation of tariffs," could compress distribution margins and impact net margins and earnings over the long term.
- Heightened competition from peers and potential loss or expiration of major customer contracts, as seen in the "previously announced customer contract expiration," could limit future revenue growth and pressure operating earnings.
- Ongoing tariff headwinds and global supply chain risks remain substantial, with GMPD segment guidance assuming a "$50 million to $75 million headwind to our results in fiscal '26 from tariffs," while further volatility could drive increased costs and impact consolidated margins and net income.
- Increasing consolidation and vertical integration among healthcare providers, payers, and retailers-combined with Cardinal's dependence on major customer relationships highlighted by the impact of contract expirations-may compress revenue streams and erode gross profit over time.
- Potential reimbursement changes and government bidding programs, such as referenced "potential changes in the reimbursement environment" and "competitive bidding coming back," specifically in the at-Home Solutions segment, could reduce top-line growth and profitability within key business lines.
Valuation
How have all the factors above been brought together to estimate a fair value?
- The analysts have a consensus price target of $264.73 for Cardinal Health based on their expectations of its future earnings growth, profit margins and other risk factors.
- However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $292.0, and the most bearish reporting a price target of just $215.0.
- In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $302.9 billion, earnings will come to $2.4 billion, and it would be trading on a PE ratio of 29.0x, assuming you use a discount rate of 7.2%.
- Given the current share price of $234.16, the analyst price target of $264.73 is 11.5% higher.
- We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.
Have other thoughts on Cardinal Health?
Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.
Create NarrativeHow well do narratives help inform your perspective?
Comments
0 commentsDisclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Read more narratives
There are no other narratives for this company.
View all narratives